2Q2024 Medtech Public Company Summary and Valuation Guide
Key Takeaways
-
Market Expectations for 2025: Analysts anticipate a significant increase in earnings per share (EPS) growth, expecting double-digit growth across the board and over 15% growth for diagnostics and consumer health segments in 2025.
-
Medtech Sector Performance: While the medtech sector showed strong performance at the beginning of 2024, valuations experienced a downturn in the second quarter, leading to broad underperformance compared to major indexes.
-
Best and Worst Performers: Natera and Insulet outperformed with gains of 18.4% and 17.8%, respectively, while Illumina, Exact Sciences, and Eurofins saw declines over 20%.
-
M&A Activity: There has been a notable increase in multibillion-dollar acquisitions in the medtech sector, with Axonics and Silk Road Medical being acquired by Boston Scientific. This suggests the market is receptive to M&A deals when the price is fair.
-
IPO Window and M&A Benefits: The limited activity in public takeovers might benefit strategic buyers looking to acquire late-stage medtech startups, potentially leading to more M&A deals.
Stock Returns
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Life Sciences
- Diagnostics
- Consumer Health
Valuations
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of March 31, 2024:
Revenue
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Consumer Health
- Life Sciences
- Diagnostics
EBITDA
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Consumer Health
- Life Sciences
- Diagnostics
Interactive Excel Data Pack
The comprehensive data pack includes forward-looking estimates and is available to PitchBook clients through the Excel plugin, offering interactive access to financial data and company information for over 55,000 public companies worldwide, along with proprietary data on over 4 million private companies.
